Revolution Medicines (RVMD) shares declined 9% in recent Monday trading after the company presented preliminary data for its RMC-6236 and RMC-6291 drug candidates in patients with several forms of cancer, including pancreatic ductal adenocarcinoma, colorectal, non-small cell lung cancer, and colorectal cancer.
The company reported updated clinical data for RMC-6236 from its Phase 1 study, which evaluated 76 patients with RAS-mutant pancreatic ductal adenocarcinoma treated with 300 mg daily.
Rash and gastrointestinal toxicities were the most common treatment-related adverse events observed, according to the company.
Additionally, data from 124 patients with RAS-mutant non-small cell lung cancer suggested that RMC-6236 was well tolerated at doses between 120 mg and 220 mg daily, but treatment-related adverse events increased at the 300 mg daily dose level.
The company said the phase 1 and phase 1b trials evaluated both RMC-6236 and RMC-6291 as monotherapies and in combination with Merck's (MRK) Keytruda chemotherapy, spanning multiple dosing levels.
The testing also spanned multiple dosing levels, generally finding there were no severe treatment-related adverse events and that the data support additional studies, it added.
Price: 52.66, Change: -5.19, Percent Change: -8.97
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。